Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November

MORRISVILLE, N.C., Oct. 01, 2018 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that enrollment in the Company’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum has fully enrolled all cohorts. Cohorts 3 and 4, SB206 12% twice-daily (BID) and 12% once-daily (QD) respectively, were recruited meaningfully ahead of schedule with enrollment completed in August.